Reliability of KRAS mutation testing in metastatic colorectal cancer patients across five laboratories

Heather Spencer Feigelson, Katrina A B Goddard, Monique A. Johnson, Kellyan C. Funk, Alanna Kulchak Rahm, Tia L. Kauffman, Dhananjay A. Chitale, Loic Le Marchand, Carolyn (Sue) Richards

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: Mutations in the KRAS gene are associated with poor response to epidermal growth factor receptor inhibitors used in the treatment of metastatic colorectal cancer. Factors influencing KRAS test results in tumor specimens include: tumor heterogeneity, sample handling, slide preparation, techniques for tumor enrichment, DNA preparation, assay design and sensitivity. We evaluated comparability and consistency of KRAS test results among five laboratories currently being used to determine KRAS mutation status of metastatic colorectal cancer specimens in a large, multi-center observational study. Findings: Twenty formalin-fixed paraffin-embedded human colorectal cancer samples from colon resections previously tested for KRAS mutations were selected based on mutation status (6 wild type, 8 codon 12 mutations, and 6 codon 13 mutations). We found good agreement across laboratories despite differences in mutation detection methods. Eighteen of twenty samples (90%) were concordant across all five labs. Discordant results are likely not due to laboratory error, but instead to tumor heterogeneity, contamination of the tumor sample with normal tissue, or analytic factors affecting assay sensitivity. Conclusions: Our results indicate commercial and academic laboratories provide reliable results for the common KRAS gene mutations at codons 12 and 13 when an adequate percentage of tumor cells is present in the sample.

Original languageEnglish (US)
Article number196
JournalBMC Research Notes
Volume5
DOIs
StatePublished - 2012

Fingerprint

Tumors
Colorectal Neoplasms
Mutation
Testing
Codon
Neoplasms
Assays
Genes
Epidermal Growth Factor Receptor
Paraffin
Formaldehyde
Contamination
Cells
Colonic Neoplasms
Tissue
Observational Studies
DNA

Keywords

  • Colorectal cancer
  • EGFR
  • KRAS
  • Laboratory error

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Reliability of KRAS mutation testing in metastatic colorectal cancer patients across five laboratories. / Feigelson, Heather Spencer; Goddard, Katrina A B; Johnson, Monique A.; Funk, Kellyan C.; Rahm, Alanna Kulchak; Kauffman, Tia L.; Chitale, Dhananjay A.; Le Marchand, Loic; Richards, Carolyn (Sue).

In: BMC Research Notes, Vol. 5, 196, 2012.

Research output: Contribution to journalArticle

Feigelson, HS, Goddard, KAB, Johnson, MA, Funk, KC, Rahm, AK, Kauffman, TL, Chitale, DA, Le Marchand, L & Richards, CS 2012, 'Reliability of KRAS mutation testing in metastatic colorectal cancer patients across five laboratories', BMC Research Notes, vol. 5, 196. https://doi.org/10.1186/1756-0500-5-196
Feigelson, Heather Spencer ; Goddard, Katrina A B ; Johnson, Monique A. ; Funk, Kellyan C. ; Rahm, Alanna Kulchak ; Kauffman, Tia L. ; Chitale, Dhananjay A. ; Le Marchand, Loic ; Richards, Carolyn (Sue). / Reliability of KRAS mutation testing in metastatic colorectal cancer patients across five laboratories. In: BMC Research Notes. 2012 ; Vol. 5.
@article{301cfb6cf8ef4168b9af8e5d0e9d611b,
title = "Reliability of KRAS mutation testing in metastatic colorectal cancer patients across five laboratories",
abstract = "Background: Mutations in the KRAS gene are associated with poor response to epidermal growth factor receptor inhibitors used in the treatment of metastatic colorectal cancer. Factors influencing KRAS test results in tumor specimens include: tumor heterogeneity, sample handling, slide preparation, techniques for tumor enrichment, DNA preparation, assay design and sensitivity. We evaluated comparability and consistency of KRAS test results among five laboratories currently being used to determine KRAS mutation status of metastatic colorectal cancer specimens in a large, multi-center observational study. Findings: Twenty formalin-fixed paraffin-embedded human colorectal cancer samples from colon resections previously tested for KRAS mutations were selected based on mutation status (6 wild type, 8 codon 12 mutations, and 6 codon 13 mutations). We found good agreement across laboratories despite differences in mutation detection methods. Eighteen of twenty samples (90{\%}) were concordant across all five labs. Discordant results are likely not due to laboratory error, but instead to tumor heterogeneity, contamination of the tumor sample with normal tissue, or analytic factors affecting assay sensitivity. Conclusions: Our results indicate commercial and academic laboratories provide reliable results for the common KRAS gene mutations at codons 12 and 13 when an adequate percentage of tumor cells is present in the sample.",
keywords = "Colorectal cancer, EGFR, KRAS, Laboratory error",
author = "Feigelson, {Heather Spencer} and Goddard, {Katrina A B} and Johnson, {Monique A.} and Funk, {Kellyan C.} and Rahm, {Alanna Kulchak} and Kauffman, {Tia L.} and Chitale, {Dhananjay A.} and {Le Marchand}, Loic and Richards, {Carolyn (Sue)}",
year = "2012",
doi = "10.1186/1756-0500-5-196",
language = "English (US)",
volume = "5",
journal = "BMC Research Notes",
issn = "1756-0500",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Reliability of KRAS mutation testing in metastatic colorectal cancer patients across five laboratories

AU - Feigelson, Heather Spencer

AU - Goddard, Katrina A B

AU - Johnson, Monique A.

AU - Funk, Kellyan C.

AU - Rahm, Alanna Kulchak

AU - Kauffman, Tia L.

AU - Chitale, Dhananjay A.

AU - Le Marchand, Loic

AU - Richards, Carolyn (Sue)

PY - 2012

Y1 - 2012

N2 - Background: Mutations in the KRAS gene are associated with poor response to epidermal growth factor receptor inhibitors used in the treatment of metastatic colorectal cancer. Factors influencing KRAS test results in tumor specimens include: tumor heterogeneity, sample handling, slide preparation, techniques for tumor enrichment, DNA preparation, assay design and sensitivity. We evaluated comparability and consistency of KRAS test results among five laboratories currently being used to determine KRAS mutation status of metastatic colorectal cancer specimens in a large, multi-center observational study. Findings: Twenty formalin-fixed paraffin-embedded human colorectal cancer samples from colon resections previously tested for KRAS mutations were selected based on mutation status (6 wild type, 8 codon 12 mutations, and 6 codon 13 mutations). We found good agreement across laboratories despite differences in mutation detection methods. Eighteen of twenty samples (90%) were concordant across all five labs. Discordant results are likely not due to laboratory error, but instead to tumor heterogeneity, contamination of the tumor sample with normal tissue, or analytic factors affecting assay sensitivity. Conclusions: Our results indicate commercial and academic laboratories provide reliable results for the common KRAS gene mutations at codons 12 and 13 when an adequate percentage of tumor cells is present in the sample.

AB - Background: Mutations in the KRAS gene are associated with poor response to epidermal growth factor receptor inhibitors used in the treatment of metastatic colorectal cancer. Factors influencing KRAS test results in tumor specimens include: tumor heterogeneity, sample handling, slide preparation, techniques for tumor enrichment, DNA preparation, assay design and sensitivity. We evaluated comparability and consistency of KRAS test results among five laboratories currently being used to determine KRAS mutation status of metastatic colorectal cancer specimens in a large, multi-center observational study. Findings: Twenty formalin-fixed paraffin-embedded human colorectal cancer samples from colon resections previously tested for KRAS mutations were selected based on mutation status (6 wild type, 8 codon 12 mutations, and 6 codon 13 mutations). We found good agreement across laboratories despite differences in mutation detection methods. Eighteen of twenty samples (90%) were concordant across all five labs. Discordant results are likely not due to laboratory error, but instead to tumor heterogeneity, contamination of the tumor sample with normal tissue, or analytic factors affecting assay sensitivity. Conclusions: Our results indicate commercial and academic laboratories provide reliable results for the common KRAS gene mutations at codons 12 and 13 when an adequate percentage of tumor cells is present in the sample.

KW - Colorectal cancer

KW - EGFR

KW - KRAS

KW - Laboratory error

UR - http://www.scopus.com/inward/record.url?scp=84862199032&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862199032&partnerID=8YFLogxK

U2 - 10.1186/1756-0500-5-196

DO - 10.1186/1756-0500-5-196

M3 - Article

C2 - 22534075

AN - SCOPUS:84862199032

VL - 5

JO - BMC Research Notes

JF - BMC Research Notes

SN - 1756-0500

M1 - 196

ER -